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Abstract
The classification of chronic pulmonary obstructive disease (COPD) into clinical and pathophysiological subsets is
not new, but increasing data is available on the relation of these different phenotypes to clinically meaningful
outcomes. This review focuses on the “emphysema-hyperinflation” (EH) phenotype, which is characterised by a
prominent loss of lung elastic recoil and hyperinflation burden that translates into marked exercise intolerance and
a heightened sense of dyspnoea.
Although no single genetic profile has been associated with the EH phenotype, recent data have shown that
certain single nucleotide polymorphisms, such as DNAH5, appear to have an effect on the preferential
development of hyperinflation in smokers. Static and dynamic hyperinflation are hallmarks of the EH
phenotype, and abnormal increases in resting lung function indices such as total lung capacity (TLC),
functional residual capacity (FRC) and inspiratory to TLC ratio (IC/TLC) seem more associated with the clinical
EH phenotype than others markers of gas trapping.
An increased level of dyspnoea on exertion and exercise intolerance are also characteristic of the EH presentation
and are likely related in part to critical mechanical constraints imposed on tidal volume expansion in situations
where ventilatory demands are increased, but also possibly on cardiac and hemodynamic anomalies related to
emphysema and hyperinflation. Importantly, the clinical relevance of the EH phenotype is underlined by the
finding that indices of hyperinflation such as IC/TLC and residual volume (RV) can be used as independent
predictors of mortality in patients with COPD.
Treatment of patients with the EH phenotype should primarily focus on smoking cessation and maximal bronchodilator
therapy. New long-acting combined bronchodilators options provide clinicians with safe and effective ways to address
the hyperinflation issue in this population. Pulmonary rehabilitation also has a positive impact on exercise tolerance,
quality of life and hyperinflation, and should be routinely considered in patients with EH presentation that remain
symptomatic despite optimal treatment, whereas as lung volume reduction techniques should be reserved for highly
selected patients.
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Introduction
The emergence of COPD phenotypes
Chronic obstructive pulmonary disease (COPD) is a signifi-
cant public health concern that has worldwide repercus-
sions as an important source of mortality and morbidity
[1–3]. Although scientific progress regarding COPD may
have been hindered by its perception as a self-inflicted and
irreversible disease [4], the last decades have witnessed an
increasing interest in research regarding the epidemio-
logical and pathophysiological aspects of COPD, as well as
the development of new therapeutic agents. Since the first
Global Initiative for Obstructive Lung Disease (GOLD)
statement was published in 2001, there has been growing
understanding of the clinical relevance of the heteroge-
neous and complex nature of the disease. Although the last
update of the GOLD statement still suggests a definition of
COPD based on lung function indices, it also clearly
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acknowledges the importance of other disease components,
such as dyspnoea, exacerbations and disability/health status
[5]. This allows clinicians to modulate their assessment of
the disease’s severity beyond the classical FEV1 criterion,
which alone is known to be an imperfect reflection of dis-
ease burden [6] and prognosis [7, 8]. Chronic activity-
related dyspnea, for example, is recognised as a better pre-
dictor of mortality [9] than FEV1 alone.
The recognition that COPD is a multifaceted entity is
far from novel [10–12], but it is only recently that its dif-
ferent clinical presentations were identified and inte-
grated as relevant potential markers of symptomatology,
response to treatment and prognosis: the so-called
COPD phenotypes [13–18].
A group of expert defined these COPD phenotypes as “a
single or combination of disease attributes that describe
differences between individuals with COPD as they relate
to clinically meaningful outcomes (symptoms, exacerba-
tions, response to therapy, rate of disease progression, or
death)” [19]. Many such phenotypes have been tentatively
described: emphysema-hyperinflation, chronic bronchitis,
and asthma-COPD overlap syndrome, the first two being
further possibly associated with the frequent or infrequent
exacerbator profile [13, 17, 20]. Of note, the term “pheno-
type” usually refers to the actual observable characteristics
and properties of an organism, which stem from the inter-
action between its genetic background and its environ-
ment. Although considerable progress has been made
regarding the genetic determinants of COPD since the se-
quencing of the human genome, there is still insufficient
data to clearly delineate a unique causative genetic com-
ponent for each of these proposed subgroups. It is there-
fore important to emphasize the clinical nature of these
phenotypes.
This review will focus on the emphysema-hyperinflation
(EH) phenotype. Although no clear and generalized defin-
ition of this phenotype has been described, we will, for the
purpose of this review, define it as a subgroup of patients
that present with predominant dyspnea, a significant em-
physema burden (assessed using either computed tomog-
raphy scanner or pulmonary function testing) and/or lung
hyperinflation (assessed using pulmonary function test-
ing), while not presenting characteristics associated with
other recognized phenotypes such as chronic bronchitis
or asthma-COPD overlap syndrome.
Review
Identification of the emphysema-hyperinflation phenotype
Genetic determinants
The observations that only a minority of smokers will
develop COPD and that there are instances of familial
clustering of COPD among relatives of patients with the
disease support the fact that genetic factors play a role
in the pathogenesis of COPD. A complete overview of
the potential genetic determinants of COPD is beyond
the scope of this text, but we briefly review some of the
evidence regarding emphysema and hyperinflation.
Single nucleotide polymorphisms (SNPs) linked to the
development of emphysema have been identified in sev-
eral candidate genes in recent years, especially following
the National Emphysema Treatment Trial (NETT) [21].
These SNPs usually involve genes related to xenobiotic
metabolism, preservation of the extracellular matrix,
host defense, control of inflammation and telomere
regulation. Polymorphisms in glutathione S-transferase
P1 (GSTP1) and microsomal epoxide hydrolase (EPHX1)
are associated with apical emphysema and rapid lung
function decline [22–25]. SNPs in EPHX1 are also re-
lated to exercise capacity, DLCO and dyspnoea [26].
Recently, the first genome-wide association study of
hyperinflation was performed in patients of the COPD-
Gene [27], Evaluation of COPD Longitudinally to Iden-
tify Predictive Surrogate Endpoints (ECLIPSE) [28] and
GenKOLS [29] studies. A SNP in dynein, axonemal,
heavy chain 5 (DNAH5) was associated with increased
computed tomography (CT) derived total lung capacity
(TLC). DNAH5 encodes a dynein found in the respira-
tory cilia and whose mutation can cause primary ciliary
dyskinesia type 3 or Kartagener syndrome. In this study,
no data relative to exercise tolerance, symptoms or other
markers of hyperinflation were available [30].
Characteristics of the EH phenotype: Hyperinflation
Static hyperinflation Central to the concept of the EH
phenotype is static hyperinflation, which refers to the re-
set of the resting relaxation volume of the respiratory
system to an abnormally high volume, and mainly results
from changes in the elastic proprieties of the lung and
chest wall [31, 32]. It is important to recognise that the
term “static” refers to the determination of lung volumes
using the static pressure-volume relaxation curve of the
respiratory system [33, 34] (see Fig. 1).
While the criteria used to diagnose airway obstruction
(using FEV1/FVC ratio) and assess its severity (using
FEV1) are uniformly recognized [5, 35], the presence and
severity of gas trapping and static hyperinflation can be
described using a plurality of indices, the most common
being residual volume (RV), functional residual capacity
(FRC), total lung capacity (TLC), RV/TLC ratio and FRC/
TLC ratio. Although no precise cut-off value for these in-
dices has been defined, it is generally accepted that lung
hyperinflation is present when they exceed either the
upper limit of normality (ULN, as defined as the upper
95 % confidence limit of a reference population) or an ar-
bitrary 120 % of the predicted value. Thus, an elevated
value of RV and/or RV/TLC implies pulmonary gas trap-
ping, while an abnormally high FRC, TLC and/or FRC/
Dubé et al. COPD Research and Practice  (2016) 2:1 Page 2 of 11
TLC ratio signify lung hyperinflation. Of note, while the
use of resting inspiratory capacity (IC) or IC/TLC ratio to
assess hyperinflation is frequent, it must be emphasized
that in some patients with significant lung hyperinflation,
end-expiratory lung volume (EELV) and TLC may in-
crease in a parallel and proportional way, leading to a pre-
served IC. In the same manner, if hyperinflation is
concomitant to other conditions influencing EELV (such
as respiratory muscle weakness) or TLC (such as intersti-
tial lung disease), IC becomes an unreliable marker of
hyperinflation.
Recent data suggest that among these indices, a larger
FRC, TLC and decreased IC/TLC are preferentially asso-
ciated with percent emphysema on CT scan, greater dys-
pnoea and lower body mass index (BMI) – all
characteristics of the EH phenotype [36].
The natural evolution of hyperinflation in patients
with COPD is unclear, but data suggest that it can
present even in patients with mild COPD, and increases
exponentially as disease severity worsens [37]. On a re-
lated note, there is increasing evidence supporting the
correlation of CT-derived emphysema assessment with
physiological markers of hyperinflation (most commonly
RV, RV/TLC and resting IC and FRC) [38–42].
Of interest is the observation that significant lung
hyperinflation may alter the measurement of forced ex-
piratory flows. During a forced expiratory manoeuvre,
thoracic gas is compressed by the increase in intratho-
racic pressures, causing a decrease in lung volume and
elastic recoil that will in turn decrease driving airflow
pressure and FEV1 [43]. Measurement of compression-
free FEV1 using body plethysmography confirms that it
is underestimated in patients with significant hyperinfla-
tion, to the extent of affecting the grading of disease se-
verity [44]. This finding supports the increasingly
prevalent notion that FEV1 alone can be misleading or
unreliable when trying to grade COPD severity.
Dynamic hyperinflation In contrast to static hyperinfla-
tion (which, as mentioned, refers to an increase of FRC
above the 95th percentile of the predicted value when the
elastic recoil pressure of the respiratory system is zero
[33]), dynamic hyperinflation (DH) refers to an “increase
of the FRC above the relaxation volume in situations
where the duration of expiration is insufficient for deflat-
ing the lung to its relaxation volume prior to the next in-
spiratory effort and where, as a result, the elastic recoil
pressure of the respiratory system becomes positive”. [33,
45, 46]. As a result, operating lung volumes progressively
shift closer to TLC, tidal volume expansion becomes lim-
ited by high intrathoracic pressures and work of breathing
is increased [47] (see Fig. 2). The discrepancy between
tidal volume expansion limitation and increasing neural
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Fig. 1 Change in end-expiratory lung volume (EELV) with COPD. EELV is set at the point at which the elastic recoil pressures of the lung and chest wall
are equal and opposite in direction. In COPD patients with hyperinflation, emphysema decreases lung elastic recoil pressure and causes a
reset of functional residual capacity, or EELV, at a higher absolute lung volume. The difference between expected (long-dashed lines) and
observed EELV (short-dashed lines) represent static hyperinflation
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increases shortness of breath [48–50], and a mechanical
dyspnoea threshold is reached when inspiratory reserve
volume (IRV) decreases to approximately 0.6-0.4 L [51].
Further increase in minute ventilation will preferentially
be accomplished by increased respiratory rate, with conse-
quently deceased expiratory time, which aggravates DH to
a greater extent.
The presence of DH is correlated to resting hyperinfla-
tion [45, 52], disease severity [48], exercise tolerance,
dyspnoea and mortality, [45, 48, 53, 54] and as such is a
hallmark of the EH phenotype.
However, the direct role of DH as a limiting factor dur-
ing exercise in COPD has been challenged by a study that
found no difference in exercise capacity or dyspnoea rat-
ing during constant work-rate cycle exercise in hyperin-
flated COPD patients at rest presenting with and without
DH [55]. In this study, although both groups of patients
showed significant resting hyperinflation, patients who did
not hyperinflate during exercise had a slightly higher
FEV1/FVC ratio and less resting lung hyperinflation
(FRC%pred and TLC%pred were less than the hyperinfla-
tors group), suggesting less airway dysfunction than the
group who hyperinflated. Given that ventilatory demand
and the volume and timing components of breathing dur-
ing exercise were similar in both groups, we can assume
that differences in IC behaviour during exercise primarily
reflected unmeasured differences in mechanical time con-
stants for lung emptying. Nonetheless, the attainment of a
critical mechanical tidal volume/IRV constraint on exer-
tion (which was similar in both groups) appeared to be a
more pivotal contributor to exercise-induced dyspnoea
than absolute DH.
Characteristics of the EH phenotype: Emphysema
Emphysema is pathologically defined as lung tissue
destruction and dilatation beyond the terminal bronchi-
oles [56]. The EH phenotype, when contrasted with
chronic bronchitis, is characterised by a larger emphy-
sema burden, and DLCO can be used to approximate













Fig. 2 Dynamic hyperinflation. This is a real-life example of a 51 years-old woman with severe COPD (FEV1/FVC ratio 0.50, FEV1 1.31 L, 47 % predicted)
who performed inspiratory capacity maneuvers during incremental cardiopulmonary exercise testing of cycle ergometer. Forced expiratory flow is shown
in full black line, and resting tidal volume in short-dashed line. At peak exercise, VT expansion is produced at the expense of inspiratory reserve volume
(long-dashed line), EELV increases and inspiratory capacity decreases. The difference in EELV between resting and exercise represents dynamic hyperinflation
(DH). TLC = total lung capacity. EELV = end-expiratory lung volume. FEV1 = forced expiratory volume in 1 s. FVC= forced vital capacity. VT = tidal volume.
IC = inspiratory capacity. DH=dynamic hyperinflation
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FEV1 in itself is more poorly related to radiological em-
physema in some [40, 61, 62], but not all [39, 41, 42, 63]
studies. These findings suggest that CT scanning may
play a role in the punctual or longitudinal assessment of
the severity of COPD, especially when emphysema is the
predominant pattern [64].
Clinical relevance of the emphysema-hyperinflation
phenotype
Respiratory symptoms and exercise tolerance
Hyperinflation and emphysema are related to respiratory
symptoms and quality of life [45, 62]. Compared with pa-
tients with COPD and normal lung volumes, those with
resting hyperinflation have higher baseline dyspnoea
[36, 65, 66] and significant intolerance to exercise
[45]. Albuquerque et al. studied a cohort of patients
with COPD and described how resting IC/TLC was
the best predictor of a low peak oxygen uptake (VO2)
during incremental cardiopulmonary testing, with a
cut-off value of 0.28 having a sensitivity and specifi-
city of 80.0 % and 89.6 % in identifying patients with
a peakVO2 of less than 60 % predicted [67]. Similarly,
Diaz et al. showed that, in a similar cohort, IC was
strongly correlated to peakVO2 and that, in patients
with resting expiratory flow limitation, it was the sole
predictor of aerobic capacity [53]. O’Donnell et al. re-
ported that, in 105 patients with COPD undergoing incre-
mental exercise testing, peakVO2 correlated best with
peak tidal volume reached, which itself was closely related
to DH. Moreover, when compared with COPD patients
with a preserved DLCO, patients with a reduced DLCO
(and, presumably, a larger emphysema burden compatible
with the EH phenotype) had lower peak VO2, larger rest-
ing hyperinflation and more frequently had dyspnoea as
exercise stopping reason, despite no difference in FEV1
between the groups [45].
The almost universal exercise intolerance of patients
with EH phenotype has repercussions in their everyday
lives, and hyperinflation again emerges as an important
predictive factor in this context. A study of 56 COPD eval-
uated the relation between lung function indices (includ-
ing a measure of DH during an activity of daily living
(ADL) task performed at the patient’s home) and average
daily physical activity. The authors found that both resting
IC/TLC ratio and ADL-induced change in IC were the
two main determinants of daily activity levels, with no sig-
nificant contribution of FEV1 [68].
Garcia-Rio et al. similarly reported that, in patients
with COPD, the presence of DH, the absolute change in
IC during exercise and the 6-minute walking distance
explained 89 % of the variance in mean daily physical ac-
tivity [69], while FEV1 correlated with activity only in
univariate analyses. Finally, in a study evaluating the
magnitude of DH during self-paced ADL across COPD
severity groups, Hannink et al. showed that DH occurs
irrespective of disease severity, but that there was a
trend for a lesser magnitude of change in EELV in the
most severe patients. This could either be explained by
the fact that GOLD IV patients have more resting hyper-
inflation and cannot generate as much “new” hyperinfla-
tion as the others, or by the fact that these patients
seemed to have performed ADL with lesser metabolic
cost (lower VO2 and minute-ventilation). Although the
study was not specifically designed to assess this, IRV
during ADL was correlated to FEV1 and decreased to
0.51 liters in GOLD IV patients, who also described a
significantly higher level of dyspnoea [52]. This seems
consistent with the notion that a critical mechanical
constraint of IRV, rather than absolute DH, relates to
exercise-induced dyspnoea.
Body mass index, muscle wasting and osteoporosis
Echoing Frank Netter’s classic representation of the
cachectic pink puffer patient, some studies have reported
a relationship between the EH phenotype and a low BMI
and/or peripheral muscle strength [36, 62, 65, 70, 71].
The pathophysiology behind the changes in body com-
position seen in some patients with COPD remains un-
clear, but evidence suggests it may be related to an
increased secretion of inflammatory cytokines [72–77].
Resistive breathing, which mimics the increased work of
breathing experienced by patients with hyperinflation,
has been shown to directly induce a systemic inflamma-
tory response [78].
In addition, serum and bronchoalveolar lavage levels
of adiponectin are higher in patients with COPD than in
healthy subjects [79], and adiponectin-deficient mice
seem protected against the development of emphysema
and inflammation in response to cigarette smoke [80]. In
humans, CT-assessed emphysema and low BMI are
closely related to serum adiponectin levels [81]. Al-
though it is still unclear whether adiponectin has a
causative role in the pathophysiology of emphysema or
is secreted in reaction to increased systemic inflamma-
tion, this cytokine shows promise as a potential marker
of COPD, and of the EH phenotype. Finally, there is in-
creasing data supporting the association of COPD and
osteoporosis. The causative mechanisms underlying this
association are still being investigated, but are likely
modulated by gender, clinical phenotype (with a signifi-
cant relationship to the severity of emphysema) and gen-
etic predisposition [82–85].
Cardiovascular disease
Both hyperinflation (by increasing intrathoracic pressures)
and emphysema (by destroying distal pulmonary vessels)
have negative consequences on cardiac and circulatory
function by decreasing ventricular preload, size and
Dubé et al. COPD Research and Practice  (2016) 2:1 Page 5 of 11
function. Barr et al. showed that, in a population-derived
sample, CT emphysema and FEV1/FVC ratio were signifi-
cantly correlated to left ventricular end-diastolic volume,
stroke volume, cardiac output, but not to left ventricular
ejection fraction [86]. Similarly, Jorgensen et al. compared
patients with significant baseline hyperinflation (mean RV
272 % predicted and mean FRC 219 % predicted) to
matched controls and found lower intrathoracic blood
volume, left and right diastolic ventricular volume in-
dexes, cardiac index and stroke volume index in patients
with hyperinflation [87]. In this study, the correlation be-
tween intrathoracic blood volume and left ventricular end
diastolic volume index highlights the role of decreased
ventricular preload in the lower cardiac function in hyper-
inflated patients.
Vassaux et al. showed that severe resting hyperinfla-
tion (IC/TLC < 0.25) was associated with decreased exer-
cise capacity and a lower peak oxygen pulse, and that
IC/TLC was strongly correlated (r = 0.95) to peak oxygen
pulse across disease severity, both in COPD patients and
in controls [88]. Watz et al. similarly showed that static
hyperinflation (evaluated using IC/TLC, FRC and RV)
correlated better with the size of the cardiac chambers
than the degree of airflow obstruction or DLCO [89].
Left ventricular diastolic dysfunction [90] and left atrial
size [91] were also reported as being altered in patients
with hyperinflation.
Whether the cardiopulmonary effects of hyperinflation
are related to clinical outcome in patients with the EH
phenotype in unclear, but there is evidence supporting the
fact that the decrease in hyperinflation induced by bron-
chodilator therapy can improve right ventricular function
[92]. In addition, as several large trials have reported
trends for a decrease in mortality with the use of broncho-
dilators and lung volume reduction surgery (LVRS) in
COPD, it is possible that part of this effect was related to
a bronchodilator- or surgery-induced decrease in hyperin-
flation and consequent unloading of the cardiocirculatory
system [13, 93–97]. In addition, the decrease in hyperin-
flation induced by bronchodilator therapy has been shown
to improve right ventricular function
Prognosis
In a large multicenter cohort of patients with COPD
(n = 689) followed for a mean of 34 months, an IC/
TLC ratio < 0.25 was a significant and independent
predictor of mortality, and globally performed better
than FEV1 alone, although not better than the
BODE index [98]. Although this study underscored
the importance of the IC/TLC ratio as a prognostic
marker in a general COPD population, the precise
proportion of “EH” or other phenotypes in this
COPD cohort was not reported.
In the medical treatment arm of the NETT study [21],
high-risk patients (defined as FEV1 < 20 % predicted and
either DLCO < 20 % predicted or homogenous emphy-
sema of CT) had a higher mortality rate. In a multivari-
ate mortality model, RV was among the independent
predictors of mortality in this cohort, as were the pres-
ence of a low BMI, DLCO, and others. In this subgroup
of patients with very severe disease, IC/TLC was only as-
sociated with mortality in univariate analyses [99].
Other characteristics of the EH phenotype have been
shown to be independent predictors of mortality, such
as CT-assessed emphysema [100], a higher dyspnoea
level [9], low BMI [100–102] and exercise (in)tolerance
[99, 103, 104].
Concerning disease evolution, emphysema [105] and
CT-derived hyperinflation [106, 107] have been shown
to be related to a faster FEV1 decline and to an in-
creased exacerbation frequency in some [108], but not
all studies [109].
Treatment
Smoking cessation remains the first and foremost thera-
peutic intervention in patients with COPD, and can sig-
nificantly reduce disease progression [110–112].
As reviewed, hyperinflation is closely related to dys-
pnoea and exercise capacity, and as such is an attractive
treatment target in patients with EH phenotype. In recent
years, many pharmacological studies have included the
evaluation of clinically relevant outcomes other than FEV1
such as hyperinflation and/or exercise capacity. However,
it is important to note that most pharmacological-related
studies have been conducted in COPD patients with no
specification of their underlying phenotype.
Bronchodilators, both short- and long-acting beta-
agonists and anticholinergics, significantly decrease
static and dynamic hyperinflation, improve IC during
exercise (delaying the reaching of a critical IRV), im-
prove dyspnoea and increase forced expiratory flows
and exercise capacity. Some also have a positive effect
on exacerbation rates, healthcare utilisation and, possibly,
mortality [93, 94, 96, 113–118]. One study highlighted the
fact that bronchodilators predominantly exert their effects
on measures of resting hyperinflation, even when little or
no change in FEV1 is observed [37]. In addition, a study
investigating the predictors of improvement in exercise
tolerance following treatment of short-acting bronchodila-
tor (ipratropium bromide, three times a day for a 3-week
period) found that an increased resting IC was the best
predictor of change in endurance time following broncho-
dilation, and that the change in FEV1 was not [119].
Long-acting beta-agonists such as salmeterol and for-
moterol have been shown to decrease resting and dy-
namic hyperinflation and increase exercise performance
[120–124], although this improvement did not always
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reach clinical significance. Indacaterol, tiotropium, gly-
copyrronium bromide and aclidinium bromide also
showed their ability to positively impact hyperinflation
and improve exercise capacity [92, 125–133].
The use of a combination of long-acting bronchodila-
tors is suggested in patients on mono-therapy who still
experience significant symptoms [134], and could be
routinely considered in patients with the EH phenotype.
The addition of a second bronchodilator provides im-
provements in lung function, symptoms and exercise
capacity compared with placebo or monotherapy, with
little increase in side effects [115, 135, 136].
The advent of new fixed-dose once-daily dual broncho-
dilator options such as indacaterol-glycopyrronium,
vilanterol-umeclidinium, olodaterol-tiotropium and (twice-
daily) formoterol-aclidinium bromide provide clinicians
and patients with effective and simpler options for maxi-
misation of bronchodilation. These combinations are at
least as effective as the simultaneous use of their individual
components (possibly via a synergistic effect [137, 138])
and significantly improve lung function compared with
monotherapy [139–145]. A positive effect on exercise tol-
erance has also been demonstrated for indacaterol-
glycopyrronium and vilanterol-umeclidinium compared
with placebo [146, 147], although the magnitude of this ef-
fect was less when compared to monotherapy with
tiotropium.
Inhaled corticosteroids (ICS), on the other hand, have
not consistently been associated with improvements in
lung function and hyperinflation [148]. The combination
of fluticasone and salmeterol was found to be superior
to placebo in increasing exercise endurance time and de-
creasing hyperinflation, but was similar to salmeterol
alone [149]. However, another study described the
greater effect of combined budesonide-formoterol on ex-
ercise endurance time compared to formoterol alone. In
addition, the addition of high-dose fluticasone to stand-
ard bronchodilator therapy resulted in a large clinically
significant increase in endurance time and decrease in
hyperinflation [150].
The NETT trial [21] showed that, in patients with se-
vere emphysema, LVRS conferred a 5-years survival ad-
vantage (risk ratio for death 0.86, p = 0.02) compared with
optimal medical therapy [151]. The LVRS group also
showed a decrease in exacerbation frequency [152], im-
proved exercise tolerance and quality of life through 3 and
4 years respectively. Patients with upper-lobe predominant
emphysema and low exercise capacity were the ones in
which LVRS was most beneficial, whereas those with very
severe lung disease (FEV1 < 20 % predicted and either
homogenous emphysema of DLCO< 20 % predicted)
showed higher mortality rates in the perioperative period.
Bronchoscopic lung volume reduction (BLVR) techniques
such as endobronchial one-way valves and coils,
instillation of biological agents and thermal vapour abla-
tion are currently under investigation as promising non-
surgical approaches to emphysema treatment [153].
Finally, comprehensive pulmonary rehabilitation (PR)
remains a cornerstone of the management of patients
with COPD [134, 154] and has a significant impact on
dyspnoea, exercise tolerance, exacerbation rates, health-
care utilization and hyperinflation [154–156]. Improve-
ments in exercise capacity are enhanced when PR is
coupled with bronchodilator therapy [157], emphasizing
the importance of a multimodal approach to therapy.
Conclusion
The use of clinically relevant phenotypes in COPD al-
lows for more coherent understanding of this heteroge-
neous disease. In this review, we highlighted the main
characteristics of the EH phenotype in COPD: a height-
ened level of dyspnoea, marked exercise intolerance re-
lated to a critical constraint on lung volume expansion
and hemodynamic consequences of hyperinflation,
metabolic wasting and an adverse prognosis that is re-
lated to the degree of air trapping. As suggested by the
Spanish GesEPOC guidelines, the management of pa-
tients with COPD can also be addressed in the light of
the clinical phenotypes. In patients with EH, treatment
should primarily focus on smoking cessation, the com-
bination of maximal bronchodilation and pulmonary re-
habilitation, while LVRS and BLVR techniques remain
an option in highly selected patients.
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